Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 698 |
| INN | Betinukibart |
| Status | Clinical |
| Drug code(s) | HB0017 |
| Brand name | None |
| mAb sequence source | mAb humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | IL-17A |
| Indications of clinical studies | Ankylosing spondylitis, Psoriasis, Phase 1 in healthy volunteers |
| Primary therapeutic area | Immune-mediated / inflammatory disorders |
| Most advanced stage of development (global) | Phase 3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | October 02, 2020 |
| Start of Phase 2 | July 15, 2023 |
| Start of Phase 3 | March 29, 2024 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Huabo Biopharm Co. Ltd. |
| Licensee/Partner | None |
| Comments about company or candidate | NCT06477237 / CTR20240521 Phase 3 in plaque psoriasis started Mar 29, 2024 CTR20230990 Phase 2 in ankylosing spondylitis started in July 2023. NCT05531682 Phase 2 in psoriasis due to start in Oct 2022. NCT05442788 Phase 1 in psoriasis started in Sep 2021. NCT04505033 is a A Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HB0017 Following a Single Dose in Adult Healthy Volunteers |
| Full address of company | 1800 Cailun Road, Zhangjiang High Tech Park, Pudong New District, Shanghai Asia China https://www.huabobio.com/en/contact.html |
Humanized IgG1 kappa, described in https://doi.org/10.1016/j.ijbiomac.2022.01.119 Described in patent ANTIBODY TARGETING INTERLEUKIN 17A AND PREPARATION METHOD AND APPLICATION THEREOF United States Patent Application 20200071394
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |